Medicare AdvantageCoverageMedium impact
MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)
Independence Blue Cross·Orthopedics, Rheumatology, Pain Management·Pharmacy
Effective date
Apr 30, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.097a for Triamcinolone Acetonide ER Injectable (Zilretta®) has been reissued and becomes effective April 30, 2025. This is a fresh pharmacy policy update that may affect coverage or billing requirements for this injectable medication used primarily for osteoarthritis treatment.
Action Required
Before April 30, 2025: Billing team must review the complete policy MA08.097a for Triamcinolone Acetonide ER Injectable (Zilretta®) to identify any changes to prior authorization requirements, coverage criteria, or billing procedures. Access the full policy details from the source URL to determine specific billing updates needed for Medicare Advantage plans.